Depression, Unipolar Clinical Trial
Official title:
Evaluation Plan for Pulsed Electro Magnetic Fields (PEMF) in a Cohort Study for Patients With Unipolar Depression, Refractory to Antidepressant Drugs. A DUAG (Danish University Antidepressant Group) Study Over 8 Weeks.
PEMF (Pulsed Electro Magnetic Fields) therapy has been used to stimulate bone repair in non-union since the 1970s. This is an accepted use, which has been approved by the Food and Drug Administration in the US. The mode of action of PEMF is based on creating small electrical fields in tissue and thereby promoting healing. Besides it has been shown that PEMF enhance regeneration of nerve fibers exposed to a lesion For treatment of depression the PEMF equipment, which are provided by the company Re5 A/S, consists of a 220 V impulse generator that creates electrical impulses and an applicator which consists of an electrical cable connected to a helmet on which there are 7 electrical coils on the inside. In comparison with the rTMS (Transcranial Magnetic Stimulation) equipment, which uses stimuli approaching neuronal firing level, the PEMF fields in human is very much lower.
Applied to cells PEMF have a stimulatory effect on intracellular tyrosine kinase activity,
especially the Src family. The Src family upregulate NMDAR (N-methyl-D-aspartate) subtype of
glutamate receptor thereby gating the production of NMDAR-dependent synaptic potentiation
that are vital for processes that underlie physiological and pathological plasticity in the
brain. Dysregulation of fibroblast growth factor receptors in frontal cortical regions of the
brain seem to be associated with depression. The fibroblast growth factors are highly
dependent on the activity of the Src family.
For treatment of depression the PEMF equipment, which are provided by the company Re5 A/S,
consists of a 220 V impulse generator that creates electrical impulses and an applicator
which consists of an electrical cable connected to a helmet on which there are 7 electrical
coils on the inside. In comparison with the rTMS equipment, which uses stimuli approaching
neuronal firing level, the PEMF fields in human are very much lower.
PEMF treatment involves placing the treatment helmet on the head and connecting it to a power
source (220 V), which leads to induction of a pulsating magnetic field. The treatment was
given for 30 min once or twice daily for 8 weeks. Participants are awake during these
treatments and sit in a chair where they can read or eat. Pilot data demonstrates that the
treatment can give mild transient nausea. No other side effects have been observed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05114824 -
Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students
|
N/A | |
Not yet recruiting |
NCT05958940 -
BioClock: Bright Light Therapy for Depressive Disorders
|
N/A | |
Completed |
NCT04916548 -
Repeated Neurocognitive Measurements in Depressed Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05767073 -
LIVES: Personalized Lifestyle Intervention for Patients With Depression
|
N/A | |
Completed |
NCT06094907 -
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
|
Phase 2 | |
Completed |
NCT04121091 -
Pramipexole to Target "Anhedonic Depression"
|
Phase 2 | |
Recruiting |
NCT06092411 -
Effects of CBT and BLT in Youth With Unipolar Depression and Evening Chronotype
|
N/A | |
Enrolling by invitation |
NCT03847688 -
Machine Learning to Predict Clinical Response to TMS
|
||
Completed |
NCT02945735 -
Gaze Contingent Feedback in Major Depressive Disorder (MDD)
|
N/A | |
Recruiting |
NCT06139159 -
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
|
N/A | |
Recruiting |
NCT05011864 -
Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression
|
N/A | |
Terminated |
NCT03537547 -
Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT03515733 -
PF-04995274 and Emotional Processing in Treatment Resistant Depression
|
Phase 1 | |
Not yet recruiting |
NCT05991232 -
Repeated Neurocognitive Measurements in Depressed Patients
|
Phase 1/Phase 2 | |
Completed |
NCT03516604 -
PF-04995274 and Emotional Processing in Un-medicated Depression
|
Phase 1 | |
Completed |
NCT03538275 -
Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
|
||
Active, not recruiting |
NCT03096886 -
Novel Neural Circuit Biomarkers of Major Depression Response to CCBT
|
N/A | |
Not yet recruiting |
NCT06462196 -
Natural History of Depression, Bipolar Disorder and Suicide Risk
|
||
Completed |
NCT01874951 -
Low-Dose Naltrexone for Depression Relapse and Recurrence
|
Phase 2 | |
Completed |
NCT03906175 -
Whole-body Hyperthermia for Mild to Moderate Depressive Disorder
|
N/A |